IL17A and tuberculosis: Due to the relatively lower TB risk of other monoclonal antibodies, including anti-IL-17A agents, a recently revised AAD-NPF guideline has suggested pre-treatment screening and subsequent yearly testing for latent TB only for patients with high risk and at the discretion of the dermatologist.